Attainment of recommended glycaemic control for people with type 1 diabetes (T1D) is challenging and requires lifelong self-management with insulin therapy. Approaches to restore pancreatic beta-cell function to reverse T1D such as islet/pancreas transplant, immunomodulatory therapies and stem cell therapies have not yielded acceptable safety and/or efficacy outcomes (1). Management of T1D therefore focuses on intensive insulin therapy to achieve near normoglycaemia and avoid long-term micro- and microvasculature complications (2). Despite improvements in insulin analogues and advances in diabetes technologies, less than 30% of people with T1D reach recommended glycaemic targets (3). Intensive insulin therapy is associated with increased risk of hypoglycaemia and weight gain (4).